These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31435872)

  • 1. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
    Yamanashi K; Chen-Yoshikawa TF; Hamaji M; Yurugi K; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Date H
    Gen Thorac Cardiovasc Surg; 2020 Feb; 68(2):142-149. PubMed ID: 31435872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab.
    Muller YD; Aubert JD; Vionnet J; Rotman S; Sadallah S; Aubert V; Pascual M
    Transplantation; 2018 Jun; 102(6):e301-e303. PubMed ID: 29521880
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
    Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
    Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
    Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving experience of treating antibody-mediated rejection following lung transplantation.
    Otani S; Davis AK; Cantwell L; Ivulich S; Pham A; Paraskeva MA; Snell GI; Westall GP
    Transpl Immunol; 2014 Aug; 31(2):75-80. PubMed ID: 25004453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.
    Yilmaz VT; Suleymanlar G; Koksoy S; Ulger BV; Ozdem S; Akbas H; Akkaya B; Kocak H
    J Invest Surg; 2016 Oct; 29(5):282-8. PubMed ID: 27002854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
    Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
    BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
    Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
    Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study.
    Perrottet N; Fernández-Ruiz M; Binet I; Dickenmann M; Dahdal S; Hadaya K; Müller T; Schaub S; Koller M; Rotman S; Moll S; Hopfer H; Venetz JP; Aubert V; Bühler L; Steiger J; Manuel O; Pascual M; Golshayan D;
    PLoS One; 2021; 16(4):e0250829. PubMed ID: 33930037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
    Von Visger J; Cassol C; Nori U; Franco-Ahumada G; Nadasdy T; Satoskar AA
    BMC Nephrol; 2019 Feb; 20(1):53. PubMed ID: 30764798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
    Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab Therapy for Rejection in Pediatric Heart Transplant.
    Erdogan I; Varan B; Sezgin A; Pirat A; Zeyneloglu P
    Exp Clin Transplant; 2018 Apr; 16(2):199-203. PubMed ID: 27210774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.